Apellis, Beam team up to test base editing against the broad field of complement disorders
Last summer, as Apellis was preparing for the approval of its potential blockbuster PNH drug Empaveli, CEO Cedric Francois sat down with his team and began plotting the post-Empaveli future.
Apellis had spent most of its 12-year history developing that one drug. The pipeline listed online consisted of seven items, six of which were different formulations or applications of the molecule. But in 2018, they started diving deeper into complement biology — the broad immunology sub-field where Empaveli operates — in hopes of expanding their reach.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.